Strategic investments in early-stage companies to drive innovation and collaboration
Simulations Plus Investor Relations
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today provided additional information on advancing its corporate allocation strategy, specifically increased focus on strategic investments and partnerships.
Simulations Plus will actively pursue investments and partnerships in early-stage technology companies aimed at accelerating software and services innovations, increasing technology leadership in computational biology and chemistry, expanding total market opportunity, and identifying potential M&A candidates.
Key investment objectives include:
- Enhance Innovation and Adoption of Emerging Technologies: Explore software and services innovation and seek deeper visibility into evolving technologies, including artificial intelligence-driven drug design (AIDD) and development.
- Grow M&A Pipeline: Seed investments and partnerships in early-stage companies are expected to broaden the opportunity pipeline and total addressable market (TAM).
- Expand Revenue Opportunities: Broaden portfolio offerings through software technology and scientific service partnerships and explore new partner revenue models.
- Drive Shareholder Returns: Optimize the combination of organic growth, operating leverage, and strategic M&A to deliver long-term sustainable returns to our stakeholders.
“Our team is very excited to launch this corporate development initiative and formalize our corporate development programs with the flexibility to make strategic investments and form joint partnerships in early-stage companies,” said Will Frederick, Chief Financial Officer and Chief Operating Officer. “Strategic acquisitions to complement organic growth and expand TAM remain a priority, and this corporate development initiative is designed to allow us to reach into relevant technologies for immediate competitive benefit and long-term support of future acquisitions.”
Chief Executive Officer, Shawn O’Connor, added, “As leaders in simulation software and consulting services, our research scientists are uniquely qualified to identify promising new technologies and services that can advance our growth objectives. Many technologies used today were conceived and developed by early-stage companies, and we believe that partnering and investing in high-potential technologies will complement our R&D efforts and keep Simulations Plus at the forefront of innovation.”
Interested parties can obtain more information here.
About Simulations Plus
Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI)/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at https://www.simulations-plus.com/. Follow us on LinkedIn | X | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.
Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to successfully integrate the Immunetrics business with our own, as well as expenses we may incur in connection therewith, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.